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1. INTRODUCTION {#apt15762-sec-0006}
===============

Inflammatory Bowel Disease (IBD) is a chronic relapsing inflammatory disease of the gastrointestinal tract primarily consisting of Crohn\'s disease (CD) and ulcerative colitis (UC). Medical management of IBD aims for lasting disease remission to prevent complications and disease progression.[^1^](#apt15762-bib-0001){ref-type="ref"}, [^2^](#apt15762-bib-0002){ref-type="ref"} While both conventional immunosuppressive agents and novel biological agents are effective for IBD treatment, inter‐individual variability in therapy response is high, both with respect to efficacy and toxicity.[^3^](#apt15762-bib-0003){ref-type="ref"} This inter‐individual variability contributes to high rates of therapeutic failure in IBD, and better patient stratification is therefore needed to maximise patient benefit and minimise the harm caused by adverse events.

Thiopurines (mercaptopurine and its prodrug azathioprine) are conventional immunomodulators commonly used to maintain disease remission in patients with IBD. However, the use of thiopurines is limited by frequently occurring adverse drug reactions, including thiopurine‐induced myelosuppression and thiopurine‐induced pancreatitis, from hereon referred to as myelosuppression and pancreatitis respectively. Myelosuppression is a dose‐dependent adverse reaction with a cumulative incidence of 7%. Most patients with myelosuppression are asymptomatic, but serious opportunistic infections require hospitalisation in 30% of the patients, with an estimated mortality of 1%.[^4^](#apt15762-bib-0004){ref-type="ref"} Genetic variants in the thiopurine S‐methyltransferase (*TPMT*) and nudix hydrolase 15 (*NUDT15*) genes, which both encode enzymes involved in thiopurine metabolism, are associated with an increased risk of myelosuppression.[^5^](#apt15762-bib-0005){ref-type="ref"}, [^6^](#apt15762-bib-0006){ref-type="ref"} Pancreatitis occurs in about 4% of thiopurine‐exposed patients,[^7^](#apt15762-bib-0007){ref-type="ref"} and the pathogenesis of this potentially life‐threatening, idiosyncratic adverse reaction remains poorly understood. The *HLA‐DQA1‐HLA‐DRB1* haplotype has been identified as a genetic determinant for pancreatitis.[^8^](#apt15762-bib-0008){ref-type="ref"}, [^9^](#apt15762-bib-0009){ref-type="ref"}

Tumour Necrosis Factor alpha (TNFα) antagonists, mainly infliximab and adalimumab, are the most commonly prescribed biologicals in the management of IBD.[^10^](#apt15762-bib-0010){ref-type="ref"} Biological therapy has transformed the management of IBD and has become the largest contribution to IBD healthcare expenditure.[^11^](#apt15762-bib-0011){ref-type="ref"} Up to 65% of patients treated with infliximab and 38% of patients treated with adalimumab will lose response due to formation of anti‐drug antibodies, a process referred to as immunogenicity.[^12^](#apt15762-bib-0012){ref-type="ref"} Concomitant use of conventional immunomodulators can reduce immunogenicity. Recently, the *HLA‐DQA1\*05* haplotype was identified as a genetic determinant of immunogenicity of TNFα antagonists.[^13^](#apt15762-bib-0013){ref-type="ref"}

Given the increasing number of available therapeutic options, and the costs associated with them, there is a clear need for biomarkers predicting individual response to therapy in order to make personalised medicine decisions. We explore pre‐treatment pharmacogenetic testing, which has the potential to maximise patient benefit by optimising drug selection and dose, and minimise the harm caused by drug toxicity. In addition, avoiding (expensive) drugs that are either ineffective or harmful by optimising the use of relatively cheap conventional drugs and achieving optimal dosing as early as possible, will lead to a significant reduction in costs.

Despite this compelling rationale for pre‐treatment pharmacogenetic testing in the context of IBD management, and the falling costs of genetic tests, the implementation of pharmacogenetic‐based guidelines in the clinic has been challenging. In this study, we show that a pharmacogenetic profile or 'passport' devised from genetic data, would provide IBD patients with personalised therapeutic recommendations based on their genotypes, leading to a potentially significant reduction in costs and therapeutic failure rates in the management of IBD.

2. METHODS {#apt15762-sec-0007}
==========

All patients with IBD treated at the University Medical Center Groningen, a large IBD‐specialised tertiary hospital, are prospectively followed using an electronic IBD‐specific electronic health record. Patients with IBD treated with thiopurines (azathioprine and/or mercaptopurine) and/or TNFα antagonists (infliximab and/or adalimumab) between January 1981 and December 2018 were included in this study. Patients were genotyped and their clinical data were collected. Each patient had been diagnosed with IBD by their gastroenterologist using endoscopic data, histological data, radiological data or a combination of these. During the study period, pharmacogenetic testing was not included as routine clinical practice. All patients provided informed written consent, and the study was approved by the medical ethical board of the University Medical Center Groningen (PSI‐UMCG \[IRB no 08/279\]).

2.1. Adjudication of patients {#apt15762-sec-0008}
-----------------------------

Each patient exposed to thiopurine therapy was adjudicated as either an affected case or an unaffected control for myelosuppression and pancreatitis. Case and control adjudication criteria are identical to criteria used in previous IBD pharmacogenetic studies [^5^](#apt15762-bib-0005){ref-type="ref"}, [^8^](#apt15762-bib-0008){ref-type="ref"} and are available in the **Supplementary Data**. All cases were adjudicated by IBD experts using a modified version of the validated Liverpool Adverse Drug Reaction Causality Assessment Tool and assigned a causality category.[^14^](#apt15762-bib-0014){ref-type="ref"} Probable myelosuppression cases needed to have demonstrated a fall in white cell count to ≤2.5 × 10^9^/L and/or a reduction in neutrophil count to ≤1.0 × 10^9^/L with a clear temporal relationship with thiopurine exposure and without confounding risk factors. In addition, definite myelosuppression cases also developed a second episode of myelosuppression upon thiopurine re‐challenge. For possible myelosuppression cases, confounding causes for the myelosuppression and/or missing data were allowed if the expert opinion still implicated thiopurines as the most likely cause. Probable pancreatitis cases needed to have developed an episode of severe abdominal pain with serum pancreatic enzymes (amylase/lipase) over two times the upper limit of normal within 3 months of starting thiopurine therapy and without confounding causes for pancreatitis. In addition, definite pancreatitis cases also had to have developed a second episode of pancreatitis upon thiopurine re‐challenge. For possible pancreatitis cases, confounding causes for the pancreatitis and/or missing data were allowed if the expert opinion still implicated thiopurines as the most likely cause. In addition to previously used pancreatitis criteria, a fourth pancreatitis causality category was added: suspected pancreatitis cases who developed severe abdominal pain matching pain associated with pancreatitis within 3 months of starting thiopurine therapy, with two independent physicians suspecting pancreatitis, but without available blood amylase or lipase measurements.

Thiopurine‐tolerant controls for both myelosuppression and pancreatitis needed to have been exposed to thiopurines for at least 8 weeks without the development of myelosuppression or pancreatitis. All thiopurine‐tolerant controls, definite and probable myelosuppression cases and all pancreatitis cases were included in subsequent analyses.

Each patient exposed to TNFα antagonist therapy was adjudicated as either an immunogenicity case or unaffected control. Patients with an anti‐drug antibody titres \>12 arbitrary units per millilitre (AU/mL), demanding drug withdrawal or start of concomitant immunomodulator therapy, were classified as immunogenicity cases. All other patients exposed to TNFα antagonists for at least 52 weeks with no signs of treatment failure to latest follow‐up or to time of drug withdrawal, or patients with an anti‐drug antibody concentration \<12 AU/mL, were adjudicated as controls.

Infliximab and adalimumab antibody titres were obtained using drug‐tolerant assays developed by Sanquin Research (Sanquin, Amsterdam, the Netherlands). ELISA was used to detect drug levels, while a radio‐immuno assay was used to detect anti‐drug antibodies. Radio‐immuno assay test results were converted into arbitrary units per millilitre by comparison with dilutions of a reference serum. The cut‐off level for a positive signal was set at 12 AU/mL (mean + 3 standard deviations) of the pre‐treatment values. Details of these assays, and comparisons to other assays have been published before.[^15^](#apt15762-bib-0015){ref-type="ref"}, [^16^](#apt15762-bib-0016){ref-type="ref"}, [^17^](#apt15762-bib-0017){ref-type="ref"}

We reason that all patients exposed to either thiopurine or TNFα antagonist therapy in our cohort are representative of future candidates for these therapies, and thus for pre‐treatment pharmacogenetic screening.

2.2. Genotype data {#apt15762-sec-0009}
------------------

All patients were genotyped using both whole‐exome sequencing data (Illumina Hiseq 2500, Illumina) and a genome‐wide genotyping array (Infinium Global Screening Array, Illumina). After quality control,[^18^](#apt15762-bib-0018){ref-type="ref"} alignment to the b37 human reference genome was performed. In total, 86.06 million high‐quality reads were generated per sample. On average, 98.85% of these reads aligned to the human genome (hg19) per sample, resulting in a \>30X read depth for 81% of the whole exome. Genetic array data were combined with whole‐exome sequencing data using PLINK v1.9.[^19^](#apt15762-bib-0019){ref-type="ref"} To account for population stratification, principal component analyses were performed using Eigenstrat v7.2.1 with 1000 Genomes Project data as reference data.[^20^](#apt15762-bib-0020){ref-type="ref"}, [^21^](#apt15762-bib-0021){ref-type="ref"} Only data from patients clustering with individuals of non‐Finnish European descent were included in subsequent pharmacogenetic analyses. After extensive quality control, genotype data were phased with the Eagle2 algorithm v2.4.[^22^](#apt15762-bib-0022){ref-type="ref"}

Based on whole‐exome sequencing data, six *TPMT* star alleles were identified, which together account for \> 90% of the variation in TPMT enzyme function in Europeans: *TPMT\*2*, *TPMT\*3A*, *TPMT\*3B*, *TPMT\*3C, TPMT\*9 and TPMT\*12*. *NUDT15* genetic variants are rare in European populations. We could identify *NUDT15\*3, NUDT15\*6 and NUDT15\*9,* which are the most common *NUDT15* variant haplotypes in Europeans.[^23^](#apt15762-bib-0023){ref-type="ref"} Genetic variation at *HLA‐DQA1\*02:01‐HLA‐DRB1\*07:01* (rs2647087) and *HLA‐DQA1\*05* (rs2097432) was defined using directly genotyped array data.

2.3. Pharmacogenetic passport {#apt15762-sec-0010}
-----------------------------

For each patient, genetic variation at *TPMT, NUDT15, HLA‐DQA1\*02:01‐HLA‐DRB1\*07:01* and *HLA‐DQA1\*05* were translated into a pharmacogenetic passport using an in‐house--developed computational pipeline (**Figure S2**).

### 2.3.1. Step 1 {#apt15762-sec-0011}

Combinations of genetic variants in *TPMT* or *NUDT15*, respectively, are referred to as haplotypes. The combinations of two haplotypes (one from each chromosome) were translated into star (\*) allele diplotypes provided by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Knowledgebase. *TMPT\*1* and *NUDT15\*1* were defined as reference.[^23^](#apt15762-bib-0023){ref-type="ref"}, [^24^](#apt15762-bib-0024){ref-type="ref"}

### 2.3.2. Step 2 {#apt15762-sec-0012}

Star allele diplotype assignments were then used to link genotypes with phenotypic function (ie enzyme metabolising activity) according to the CPIC. Patients carrying one deleterious haplotype (ie other than the reference haplotype) in *TPMT* or *NUDT15* are intermediate thiopurine metabolisers. Patient carrying two deleterious haplotypes (eg *TPMT\*2/TPMT\*3A*) are poor thiopurine metabolisers.

### 2.3.3. Step 3 {#apt15762-sec-0013}

In this step, phenotypic function of TPMT and NUDT15 and *HLA *genetic variation were translated into a genetic risk of drug‐related effects.

*Step 3a*. Enzyme metabolising activity for TPMT and NUDT15 was translated into a predicted risk of myelosuppression. Intermediate metabolisers are at intermediate risk of myelosuppression, while poor metabolisers are at high risk of myelosuppression.

*Step 3b*. Patients homozygous at *HLA‐DQA1\*02:01‐HLA‐DRB1\*07:01* were referred to as patients at high risk of pancreatitis. In this study, patients heterozygous at *HLA‐DQA1\*02:01‐HLA‐DRB1\*07:01* and homozygous reference haplotype carriers were referred to as having a normal risk of pancreatitis.

*Step 3c*. Patients carrying at least one *HLA‐DQA1\*05* risk allele (ie heterozygous or homozygous) were referred to as patients at high risk of immunogenicity. In this study, homozygous reference haplotype carriers were referred to as having a normal risk of immunogenicity.

### 2.3.4. Step 4 {#apt15762-sec-0014}

In this step, genetic risks were translated into therapeutic recommendations. Therapeutic recommendations regarding *TPMT* and *NUDT15* genetic variation are in line with CPIC guidelines.[^23^](#apt15762-bib-0023){ref-type="ref"} It remains poorly understood how genetic variation in *HLA‐DQA1\*02:01‐HLA‐DRB1\*07:01* and the *HLA‐DQA1\**05 risk allele predisposes to pancreatitis or immunogenicity, but our recommendations are in line with previously proposed strategies.[^8^](#apt15762-bib-0008){ref-type="ref"}, [^9^](#apt15762-bib-0009){ref-type="ref"}, [^13^](#apt15762-bib-0013){ref-type="ref"}

*Step 4a*. Patients at intermediate risk of myelosuppression should receive a reduced starting dose (30%‐80% of target dose). For patients at high risk of myelosuppression, alternative treatment should be considered. For patients at normal risk of myelosuppression, starting dose does not need to be altered.

*Step 4b*. For patients at high risk of pancreatitis, an alternative treatment should be considered. We do not propose drug avoidance in patients heterozygous at *HLA‐DQA1\*02:01‐HLA‐DRB1\*07:01* (2.5‐fold increased risk of pancreatitis) because the high variant carrier frequency would mean drug avoidance in over one third of patients tested. For patients at normal risk of pancreatitis, starting doses do not need to be altered.

*Step 4c*. Concomitant immunomodulator therapy to prevent antibody development is proposed for patients at high genetic risk of immunogenicity. Patients at normal risk of immunogenicity, intolerant to immunomodulators or patients who are at high risk of opportunistic infections might be treated with TNFα antagonist monotherapy.

### 2.3.5. Step 5 {#apt15762-sec-0015}

In this step, our computational pipeline combined all of the above data into one 'pharmacogenetic passport' per patient. This pharmacogenetic passport may be used to aid therapeutic decisions.

2.4. Case‐control analyses {#apt15762-sec-0016}
--------------------------

Clinical data were compared between cases and exposed controls for myelosuppression, pancreatitis and immunogenicity respectively. Continuous data were described using medians and interquartile ranges, and compared using the Mann‐Whitney test. Categorical data were described as number and percentage, and compared using the Chi‐square test or Fisher exact test. Weight‐adjusted thiopurine dose (milligrams per kilograms) was calculated using the following formulas for mercaptopurine (mercaptopurine dose in milligrams × 2.08/weight in kilograms) and azathioprine (azathioprine dose in milligrams/weight in kilograms). The association of *TPMT* and/or *NUDT15* genetic variation and weight‐adjusted thiopurine dose with myelosuppression and the association of *HLA‐DQA1\*05* and use of combination therapy with immunogenicity were assessed using multivariable regression analyses. No genome‐wide association study was performed because identifying novel pharmacogenetic interactions was not an aim of this study.

2.5. Clinical efficacy estimates {#apt15762-sec-0017}
--------------------------------

Predicted clinical efficacy estimates (sensitivity, specificity, negative predictive value and positive predictive value) and numbers needed to genotype, numbers needed to treat and numbers needed to harm were calculated using previously published methods.[^5^](#apt15762-bib-0005){ref-type="ref"}, [^25^](#apt15762-bib-0025){ref-type="ref"}, [^26^](#apt15762-bib-0026){ref-type="ref"} These estimates assumed drug‐response incidence estimates from literature,[^4^](#apt15762-bib-0004){ref-type="ref"}, [^7^](#apt15762-bib-0007){ref-type="ref"} the above‐mentioned pharmacogenetic‐based treatment strategies, genotype frequencies from our nation‐wide Dutch IBD cohort and the odds ratio (OR) of the genotype‐phenotype association from our present study (Table S1A‐H).

We first calculated estimates for each pharmacogenetic predictor separately. These were then incorporated into clinical efficacy estimates for a combined IBD pharmacogenetic passport. The number needed to genotype, number needed to treat and number needed to harm to prevent one case (ie of either thiopurine toxicity or immunogenicity of TNFα antagonists) were calculated for a scenario in which an IBD pharmacogenetic genetic passport was established prior to start of either thiopurine or TNFα antagonist therapy. Using the retrospective treatment‐response data from our entire cohort of patients with IBD, we then show the potential consequences of our proposed pharmacogenetic‐based treatment strategies. All statistical calculations were performed using R 3.5.1 (R Foundations for Statistical Computing, Vienna, Austria).

3. RESULTS {#apt15762-sec-0018}
==========

We identified 710 patients with IBD who were exposed to thiopurines and/or TNFα antagonists. Of these patients, 695 (98%) were exposed to thiopurines (azathioprine 586 \[84%\]; mercaptopurine 109 \[16%\]) and 376 (53%) were exposed to TNFα antagonist therapy (infliximab 284 \[76%\]; adalimumab 92 \[24%\]) (Table [1](#apt15762-tbl-0001){ref-type="table"}).

###### 

Patient characteristics of IBD patients exposed to thiopurines. *P*‐values refer to comparisons between cases and controls

  Characteristic                                      Patients exposed to thiopurines (n = 695)   Thiopurine‐induced myelosuppression cases (n = 29)   Thiopurine‐induced myelosuppression controls (n = 470)   *P*‐values                                          Thiopurine‐induced pancreatitis cases (n = 38)   Thiopurine‐induced pancreatitis controls (n = 555)   *P*‐values
  --------------------------------------------------- ------------------------------------------- ---------------------------------------------------- -------------------------------------------------------- --------------------------------------------------- ------------------------------------------------ ---------------------------------------------------- ------------
  Gender, No. (%)                                                                                                                                                                                                                                                                                                                                                         
  Female                                              409 (59%)                                   19 (66%)                                             272 (58%)                                                0.54                                                27 (71%)                                         326 (59%)                                            0.19
  Male                                                286 (41%)                                   10 (34%)                                             198 (42%)                                                11 (29%)                                            229 (41%)                                                                                             
  Age, median (IQR), y                                47 (23)                                     44 (31)                                              47 (24)                                                  0.72                                                43 (23)                                          46 (24)                                              0.31
  Type of IBD diagnosis, No. (%)                                                                                                                                                                                                                                                                                                                                          
  Crohn\'s disease                                    404 (58%)                                   19 (66%)                                             273 (58%)                                                0.32                                                29 (76%)                                         320 (58%)                                            0.07
  Ulcerative colitis                                  267 (38%)                                   8 (28%)                                              182 (39%)                                                8 (21%)                                             218 (39%)                                                                                             
  IBD unclassified                                    24 (3%)                                     2 (7%)                                               15 (3%)                                                  1 (3%)                                              17 (3%)                                                                                               
  Type of thiopurine, No. (%)                                                                                                                                                                                                                                                                                                                                             
  Azathioprine                                        586 (84%)                                   22 (76%)                                             408 (87%)                                                0.17                                                32 (84%)                                         472 (85%)                                            1 
  Mercaptopurine                                      109 (16%)                                   7 (24%)                                              62 (13%)                                                 6 (16%)                                             83 (15%)                                                                                              
  Weight‐adjusted thiopurine dose, mean (SD), mg/kg   1.88 (0.62)                                 2.17 (0.60)                                          1.85 (0.62)                                              0.01                                                1.88 (0.53)                                      1.83 (0.65)                                          0.81
  *NUDT15* haplotype                                                                                                                                                                                                                                                                                                                                                      
  Reference/reference                                 680 (98%)                                   24 (83%)                                             466 (99%)                                                7.88E‐05[^a^](#apt15762-note-0006){ref-type="fn"}   38 (100%)                                        544 (98%)                                            0.80
  Reference/variant                                   13 (2%)                                     4 (14%)                                              4 (1%)                                                   0 (0%)                                              11 (2%)                                                                                               
  Variant/variant                                     2 (0.3%)                                    1 (3%)                                               0 (0%)                                                   0 (0%)                                              0 (0%)                                                                                                
  *TPMT* haplotype                                                                                                                                                                                                                                                                                                                                                        
  Reference/reference                                 628 (90%)                                   23 (79%)                                             434 (92%)                                                0.065[^a^](#apt15762-note-0006){ref-type="fn"}      34 (89%)                                         509 (92%)                                            0.86
  Reference/variant                                   67 (10%)                                    6 (21%)                                              36 (8%)                                                  4 (11%)                                             46 (8%)                                                                                               
  Thiopurine metabolism                                                                                                                                                                                                                                                                                                                                                   
  Normal metaboliser                                  617 (89%)                                   18 (65%)                                             432 (92%)                                                4.55E‐05[^b^](#apt15762-note-0007){ref-type="fn"}   34 (89%)                                         500 (90%)                                            1
  Intermediate metaboliser                            76 (11%)                                    10 (32%)                                             38 (8%)                                                  4 (11%)                                             55 (10%)                                                                                              
  Poor metaboliser                                    2 (0.3%)                                    1 (3%)                                               0 (0%)                                                   0 (0%)                                              0 (0%)                                                                                                
  *HLA‐DQA1‐HLA‐DRB1* haplotype                                                                                                                                                                                                                                                                                                                                           
  Reference/reference                                 416 (60%)                                   21 (71%)                                             276 (59%)                                                0.42                                                17 (45%)                                         334 (60%)                                            0.14
  Reference/variant                                   284 (41%)                                   8 (29%)                                              172 (37%)                                                19 (50%)                                            199 (36%)                                                                                             
  Variant/variant                                     31 (4%)                                     0 (0%)                                               22 (5%)                                                  2 (5%)                                              22 (5%)                                                                                               

Abbreviations: HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IQR, inter‐quartile range; No., number; NUDT15, nudix hydrolase 15; SD, standard deviation; TPMT, thiopurine S‐methyltransferase.

*P*‐values from multivariate logistic regression analyses including *TPMT* variant status, *NUDT15* variant status and weight‐adjusted thiopurine dose.

*P*‐values from multivariate logistic regression analyses including thiopurine metabolism and weight‐adjusted thiopurine dose. *NUDT15* heterozygotes are pooled with *NUDT15* homozygotes in multivariate logistic regression analyses.

John Wiley & Sons, Ltd

3.1. Case‐control analyses {#apt15762-sec-0019}
--------------------------

We first performed case‐control analyses for each pharmacogenetic predictor separately (ie for myelosuppression, pancreatitis or immunogenicity). ORs from these pharmacogenetic case‐control analyses were used as input for clinical efficacy calculations.

### 3.1.1. Thiopurine‐induced myelosuppression {#apt15762-sec-0020}

Of the 695 patients exposed to thiopurines, we identified 29 (4.2%) cases and 470 (68%) controls for myelosuppression. The remaining 196 (28%) patients did not meet our stringent case/control adjudication criteria and were excluded. Myelosuppression cases received a higher weight‐adjusted thiopurine dose compared with controls (2.17 mg/kg vs 1.85 mg/kg; *P = *0.01). There were no differences between cases and controls when comparing gender, age, IBD diagnosis or type of thiopurine used. Univariate analysis revealed that carriage of any variant in *TPMT* (OR 3.13 \[95% CI 1.11‐7.80\]; *P* = 0.02) or *NUDT15* (OR 24.3 \[95% CI 6.06‐104\]; *P* = 5.67E‐6) was associated with myelosuppression. Multivariable regression analyses revealed that carriage of any variant in *NUDT15* (OR 20.2 \[95% CI 4.4‐94.4\]; *P = 7.88E‐05*) and weight‐adjusted thiopurine dose (OR 2.69 \[95% CI 1.39‐5.26\]; *P = *3.41E‐03) were independently associated with myelosuppression (Table [1](#apt15762-tbl-0001){ref-type="table"}). The association of *TPMT* with myelosuppression failed to reach independent statistical significance using multivariable regression (OR 2.86 \[95% CI 0.84‐8.17\]; *P = *0.065).

### 3.1.2. Thiopurine‐induced pancreatitis {#apt15762-sec-0021}

Of 695 patients exposed to thiopurines, we identified 38 (5.5%) cases and 555 (80%) controls for pancreatitis. The remaining 102 (15%) patients did not meet stringent case/control adjudication criteria and were excluded. There were no differences between cases and controls in gender, age, IBD diagnosis, type of thiopurine used or weight‐adjusted dose. Carriage of the *HLA‐DQA1‐HLA‐DRB1* risk haplotype was not significantly associated with the risk of pancreatitis when using a dominant genetic model (OR 1.87 \[95% CI 0.97‐3.66\]; *P* = 0.064) or when using an additive genetic model (*P* = 0.14) (Table [1](#apt15762-tbl-0001){ref-type="table"}).

### 3.1.3. Immunogenicity of TNFα antagonists {#apt15762-sec-0022}

Of 376 patients exposed to TNFα antagonist therapy, we identified 85 (23%) cases and 194 (52%) controls for immunogenicity. The remaining 97 (26%) patients did not meet our stringent case/control adjudication criteria and were excluded. There were no differences between cases and controls when comparing gender and type of drug. Immunogenicity cases less frequently received concomitant immunomodulator therapy (32% vs 54%; *P* = 1.2E‐4), used TNFα antagonist therapy for a shorter period of time (57 weeks vs 244 weeks; *P* = 2.44E‐14), were of higher age (46 years old vs 42 years old, *P* = 0.03) and were less frequently diagnosed with CD (69% vs 85%, *P* = 0.01), compared with controls. Multivariable regression analysis revealed that the use of combination therapy (OR = 0.34 \[95% CI 0.19‐0.60\], *P* = 2.33E‐4) and CD (OR = 0.38 \[95% CI 0.20‐0.72\], *P* = 3.26E‐3) was significantly associated with a decreased risk of immunogenicity, while carriage of the *HLA‐DQA1\*05* haplotype increased the risk. However, this genetic association failed to reach statistical significance in our multivariate model (OR = 1.65 \[95% CI 0.95‐2.85\], *P* = 0.075) (Table [2](#apt15762-tbl-0002){ref-type="table"}).

###### 

Patient characteristics of patients with IBD exposed to TNFα antagonists. P‐values refer to comparisons between cases and controls

  Characteristic                         Patients exposed to TNFα antagonists (n = 376)   Immunogenicity of TNFα antagonists cases (n = 85)   Immunogenicity of TNFα antagonists controls (n = 194)   *P*‐values
  -------------------------------------- ------------------------------------------------ --------------------------------------------------- ------------------------------------------------------- ------------------------------------------------
  Gender, No. (%)                                                                                                                                                                                     
  Female                                 246 (65%)                                        59 (69%)                                            117 (60%)                                               0.19
  Male                                   130 (35%)                                        26 (31%)                                            77 (40%)                                                
  Age, median (IQR), y                   47 (21)                                          46 (27)                                             42 (21)                                                 0.03
  Type of IBD diagnosis, No. (%)                                                                                                                                                                      
  Crohn\'s disease                       278 (74%)                                        59 (69%)                                            164 (85%)                                               0.01
  Ulcerative colitis                     85 (23%)                                         23 (27%)                                            25 (13%)                                                
  IBD‐unclassified                       13 (3%)                                          3 (4%)                                              5 (3%)                                                  
  Type of TNFα antagonist, No (%)                                                                                                                                                                     
  Infliximab                             284 (76%)                                        63 (74%)                                            140 (72%)                                               0.10
  Adalimumab                             92 (24%)                                         22 (26%)                                            54 (28%)                                                
  Concomitant immunomodulator, No. (%)                                                                                                                                                                
  No                                     198 (53%)                                        59 (69%)                                            88 (45%)                                                3.5E‐4
  Yes                                    178 (47%)                                        26 (31%)                                            106 (55%)                                               
  Duration of use, median (IQR), w       206 (314)                                        18 (161)                                            200 (348)                                               6.84E‐7
  *HLA‐DQA1\*05* haplotype                                                                                                                                                                            
  Reference/reference                    227 (60%)                                        45 (53%)                                            123 (63%)                                               0.075[^a^](#apt15762-note-0009){ref-type="fn"}
  Reference/variant                      125 (33%)                                        33 (39%)                                            60 (31%)                                                
  Variant/variant                        24 (6%)                                          7 (8%)                                              11 (6%)                                                 

Abbreviations: HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IQR, inter‐quartile range; No., number.

*P*‐value from multivariate logistic regression analysis including type of IBD diagnosis, age, concomitant immunomodulator use and *HLA‐DQA1*\*05 variant status, using a dominant genetic model.

John Wiley & Sons, Ltd

3.2. Clinical efficacy estimates {#apt15762-sec-0023}
--------------------------------

We next assessed the clinical efficacy of pharmacogenetic testing for three applications: (a) to predict thiopurine toxicity (ie myelosuppression and pancreatitis) prior to starting thiopurine treatment, (b) to predict immunogenicity prior to starting TNFα antagonist therapy and (c) to predict both thiopurine toxicity and immunogenicity of TNFα antagonists prior to starting either thiopurine or TNFα antagonist therapy (ie an IBD pharmacogenetic passport).

### 3.2.1. Thiopurine toxicity {#apt15762-sec-0024}

Of 695 patients exposed to thiopurines, 590 (85%) were at low genetic risk of thiopurine toxicity, 72 (10%) were at intermediate risk of thiopurine toxicity (ie intermediate thiopurine metabolisers), and 33 (5%) were at high genetic risk of thiopurine toxicity (2 \[0.3%\] poor thiopurine metaboliser and 31 \[5%\] *HLA‐DQA1‐HLA‐DRB1* homozygotes). Four patients (0.6%) were both homozygous at the *HLA‐DQA1‐HLA‐DRB1* haplotype and intermediate thiopurine metabolisers and they were thus classified as being at high genetic risk of thiopurine toxicity. Among patients at intermediate risk of thiopurine toxicity for whom dose reduction would be recommended, we identified 11 (15%) patients who developed myelosuppression and 34 (47%) patients with uncomplicated sustained thiopurine use. Among patients at high genetic risk of thiopurine toxicity for whom drug avoidance would be recommended, we identified 3 (9%) patients who developed either myelosuppression or pancreatitis and 21 (64%) patients with uncomplicated sustained thiopurine use (Figure [1](#apt15762-fig-0001){ref-type="fig"}). Again, a number of patients did not meet case/control criteria.

![Flowchart representing current therapeutic outcomes (past) and proposed pharmacogenetic‐guided treatment strategies (future). Patients defined as candidates for therapy in this figure were exposed to either thiopurines or TNFα antagonists and are hypothesised to be representative of future candidates. Toxicity refers to either thiopurine‐induced myelosuppression or thiopurine‐induced pancreatitis. Antibodies refers to the formation of anti‐drug antibodies to TNFα antagonists, a process referred to as immunogenicity. Patients in red boxes would receive alternative treatment strategies based on pharmacogenetic testing. IBD: inflammatory bowel disease; TNFα: Tumour Necrosis Factor alpha](APT-51-1105-g001){#apt15762-fig-0001}

We calculated a number needed to genotype of 39, a number needed to treat of 7 and a number needed to harm of 5 to prevent one case of thiopurine toxicity. This means that for every 39 patients genotyped prior to starting thiopurine therapy, 7 will test positive for a predictive variant of thiopurine toxicity and 2 of them would have developed thiopurine toxicity without pharmacogenetic‐guided therapy. However, if these seven patients had received dose reduction or drug avoidance, depending on their predicted genetic risk, one case of thiopurine toxicity would have been prevented. This assumes an overall risk of 7% for myelosuppression [^4^](#apt15762-bib-0004){ref-type="ref"} and 4% for pancreatitis,[^7^](#apt15762-bib-0007){ref-type="ref"} an incidence of poor thiopurine metabolisers of 0.27% (nation‐wide Dutch IBD cohort) and an incidence of 6.7% for *HLA‐DQA1‐HLA‐DRB1* homozygotes (nation‐wide Dutch IBD cohort) (Table S1A‐E).

### 3.2.2. Immunogenicity of TNFα antagonists {#apt15762-sec-0025}

Among 376 patients exposed to TNFα antagonist therapy, 149 (40%) patients were genetically at risk of immunogenicity. Among these 149 patients, 40 (27%) developed immunogenicity, while 71 (48%) did not (Figure [1](#apt15762-fig-0001){ref-type="fig"}). Fifteen of 40 (38%) of these patients received concomitant immunomodulator therapy, which was taken into account in subsequent clinical efficacy calculations. Again, a number of patients did not meet case/control criteria.

We calculated a number needed to genotype of 32, a number needed to treat of 13 and a number needed to harm of 8 to prevent one case of immunogenicity. This means that for every 32 patients genotyped prior to starting TNFα antagonist therapy, 13 will test positive for the *HLA‐DQA1\*05* haplotype and 5 would have developed immunogenicity without pharmacogenetic‐guided combination therapy. However, if these patients had received concomitant immunomodulator therapy, one case of immunogenicity would have been prevented. This assumes an overall risk of immunogenicity of 30% (this cohort), an *HLA‐DQA1\*05* variant carrier frequency of 39% (nation‐wide Dutch IBD cohort) and subsequent prescription of a concomitant immunomodulator therapy for patients genetically at risk (Table S1E‐H).

### 3.2.3. IBD pharmacogenetic passport {#apt15762-sec-0026}

To explore the potential benefits of an IBD pharmacogenetic passport, we combined clinical efficacy estimates for preventing thiopurine toxicity and immunogenicity of TNFα antagonists into an overall predicted efficacy. In our total cohort of 710 IBD patients, 150 adverse drug responses occurred (ie either thiopurine toxicity or immunogenicity of TNFα antagonists). An IBD pharmacogenetic passport would have predicted 54 (36%) of these adverse drug responses, while 96 (64%) cases would not have been predicted (Figure [1](#apt15762-fig-0001){ref-type="fig"}).

We calculated a number needed to genotype of 24, a number needed to treat of 9 and a number needed to harm of 6 to prevent one adverse drug response (ie myelosuppression, pancreatitis or immunogenicity). This means that, for every 24 candidates for either thiopurine or TNFα antagonist therapy who were genotyped prior to starting treatment, nine patients would test positive for a predictive variant and three of them would have developed an adverse drug response without pharmacogenetic‐guided alternative therapy. However, if a pharmacogenetic‐guided alternative treatment strategy had been applied, one adverse drug response would have been prevented. This calculation makes the same assumptions for separate clinical efficacy estimates that we used above, and a frequency of thiopurine use of 98% relative to a frequency of TNFα antagonist use of 53% based on this cohort (Supplementary Data: IBD pharmacogenetic passport).

4. DISCUSSION {#apt15762-sec-0027}
=============

This real‐world IBD cohort provides clinical efficacy estimates for the implementation of an IBD pharmacogenetic passport including genetic variants predictive of both thiopurine toxicity and immunogenicity of TNFα antagonists. If such an IBD pharmacogenetic passport was incorporated into clinical guidelines, better patient stratification would lead to a significant reduction in potentially life‐threatening thiopurine toxicity and higher TNFα antagonist therapy response rates.

Both *TPMT* and *NUDT15* encode enzymes involved in thiopurine metabolism and genetic variation in these genes can lead to deficient thiopurine metabolism. Hence, 'normal' starting doses are generally 'high' for patients with defective *TPMT* or *NUDT15* alleles.[^23^](#apt15762-bib-0023){ref-type="ref"}, [^27^](#apt15762-bib-0027){ref-type="ref"} Indeed, patients carrying defective *TPMT* or *NUDT15* alleles are at increased risk of thiopurine‐induced myelosuppression. We could not replicate the association between *TPMT* and myelosuppression using a multivariate model, probably due to the relatively small sample size. However, we believe there is enough evidence to support this well‐established association.[^6^](#apt15762-bib-0006){ref-type="ref"}, [^23^](#apt15762-bib-0023){ref-type="ref"}, [^28^](#apt15762-bib-0028){ref-type="ref"} Pharmacogenetic‐guided dose reduction decreases the risk of myelosuppression in these patients without compromising therapeutic efficacy.[^29^](#apt15762-bib-0029){ref-type="ref"}, [^30^](#apt15762-bib-0030){ref-type="ref"} Our data show the predicted efficacy of pre‐treatment pharmacogenetic testing including both *TPMT* and *NUDT15.*

Genetic variation in *HLA‐DQA1‐HLA‐DRB1* is a determinant of thiopurine‐induced pancreatitis, although the mechanism for this remains elusive. We used less stringent criteria for pancreatitis, compared to previous studies, by including suspected cases for whom no biochemical or radiological evidence was obtained. Nevertheless, by doing so, the incidence of pancreatitis in our cohort was similar to what is reported in literature.[^7^](#apt15762-bib-0007){ref-type="ref"}, [^31^](#apt15762-bib-0031){ref-type="ref"} The relatively small sample size might explain why we did not replicate the association. Our data show that, if patients were screened for genetic variants in *TPMT*, *NUDT15* and *HLA*‐*DQA1‐HLA‐DRB1*, 39 patients would need to be genotyped to prevent one case of thiopurine toxicity.

It is only recently that *HLA‐DQA1\*05* has been associated with an increased risk of immunogenicity of TNFα antagonists in which the formation of antibodies targeting the TNFα antagonists leads to treatment failure or adverse drug reactions. Although concomitant use of immunomodulators can reduce the risk of immunogenicity, there are concerns about the safety of this combination therapy. Pre‐treatment *HLA‐DQA1\*05* genetic testing can identify patients at increased risk of immunogenicity and may aid targeted use of combination therapy. Our data show that 32 patients would need to be genotyped prior to starting TNFα antagonist treatment to prevent one patient from developing immunogenicity.

Currently, American Gastroenterology Association and British Society of Gastroenterology guidelines recommend *TPMT* testing prior to thiopurine therapy in addition to regular hematologic monitoring, while the European Crohn´s and Colitis Organisation guidelines do not recommend any pre‐treatment testing.[^32^](#apt15762-bib-0032){ref-type="ref"}, [^33^](#apt15762-bib-0033){ref-type="ref"}, [^34^](#apt15762-bib-0034){ref-type="ref"} Pharmacogenetic testing prior to TNFα antagonist therapy has not been implemented in routine clinical practice. Insufficient evidence to support clinical efficacy and lack of specialised training for interpretation of complex pharmacogenetic data have so far prevented pharmacogenetic testing from being widely implemented into clinical care. To our knowledge, this study is the first to combine multiple IBD gene‐drug interactions into clinical efficacy estimates. Combining clinical efficacy estimates of thiopurine toxicity and immunogenicity of TNFα antagonists into an overall predicted efficacy, we show that 24 patients need to be genotyped to prevent one of these adverse drug responses.

Our proposed thiopurine dosing strategies based on *TPMT* and *NUDT15* genotypes are in line with guidelines proposed by the Clinical Pharmacogenetics Implementation Consortium.[^23^](#apt15762-bib-0023){ref-type="ref"} Prospective studies are needed to explore the optimal treatment strategy based on both *HLA* genetic variants, which will be a trade‐off between the acceptable risk of adverse reactions and a more timely and systematic progression to other (expensive) IBD therapies. Our proposed algorithm excludes patients homozygous at *HLA‐DQA1‐HLA‐DRB1* from using thiopurines, while allowing patients heterozygous at this locus to be exposed to thiopurines. This proposed algorithm is based on the high risk (\~17%) of pancreatitis in homozygotes,[^8^](#apt15762-bib-0008){ref-type="ref"} the wide availability of alternative drugs and the relatively low frequency of homozygotes (7%). In contrast, drug avoidance in patients heterozygous at *HLA‐DQA1‐HLA‐DRB1* (\~9% risk of pancreatitis) would mean that more than one third of patients would be excluded from thiopurine use.

Pre‐treatment pharmacogenetic testing can maximise patient benefit and minimise harm. Moreover, pharmacogenetic testing has the potential to significantly reduce costs associated with IBD treatment, mainly by reducing costs associated with TNFα antagonist treatment failure and on hospitalisation for adverse drug reactions.[^11^](#apt15762-bib-0011){ref-type="ref"} Approximately 30% of the patients experiencing thiopurine‐induced myelosuppression ultimately require hospitalisation.[^4^](#apt15762-bib-0004){ref-type="ref"} This hospitalisation is associated with an estimated cost of \$5,800 per patient.[^4^](#apt15762-bib-0004){ref-type="ref"}, [^11^](#apt15762-bib-0011){ref-type="ref"} Hospitalisation is necessary for 57% of the patients with thiopurine‐induced pancreatitis, with an estimate cost of \$33,740 per hospitalisation per patient.[^35^](#apt15762-bib-0035){ref-type="ref"}, [^36^](#apt15762-bib-0036){ref-type="ref"} We estimate the costs of a genome‐wide genotyping array, designed to specifically tag pharmacogenetic predictors, to be approximately \$50 per individual. Based on an overall "number needed to genotype" of 24, the costs to prevent one adverse drug reaction will be \$1,200. Given these numbers, an IBD pharmacogenetic passport should be considered as cost effective to optimise IBD treatment.

We used a combination of whole‐exome sequencing and a genome‐wide genotyping array to reliably identify genetic variation in *TPMT, NUDT15* and *HLA.* With falling costs and wider availability of genotyping, future studies should explore which is the most cost‐effective genotyping platform that is also easy to implement in routine medical care. Furthermore, clinical efficacy estimates presented in this study are calculated using retrospective case‐control analyses, while randomised controlled trials are still considered the gold standard for clinical efficacy studies. However, randomised controlled trials often fail to produce actionable results, since outcomes are averaged across the entire population per study arm, whereas in personalised medicine, treatment is based on the individual patient. Retrospective studies like this present study should be used as a starting point for prospective studies evaluating clinically implemented pharmacogenetic testing.

In conclusion, this is the first study to describe the consequences of pre‐treatment pharmacogenetic testing for multiple gene‐drug interactions using a real‐world IBD cohort. We illustrate that pre‐treatment pharmacogenetic testing can optimise patient benefit and minimise harm. These findings show the predicted efficacy of pharmacogenetic testing prior to start of thiopurine or TNFα antagonist therapy in patients with IBD.
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